New Insights into Surgical Treatment of Hepatocellular Carcinoma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (31 March 2024) | Viewed by 954
Special Issue Editor
2. UMR Inserm 1275 CAP Paris-Tech, Lariboisière Hospital, Paris-Cité University, Paris, France
3. Toronto Organ Preservation Laboratory, Department of Multi Organ Transplant, University Health Network, Toronto, ON, Canada
Interests: liver cancer; pancreatic cancer; HPB surgery; liver transplantation; minimally invasive surgery; organ machine perfusion; liver regeneration; oncogenomic; regulatory T-cell therapy; biostatistical computing
Special Issue Information
Dear Colleagues,
Hepatocellular carcinoma (HCC) stands as the sixth most common cancer and the fourth most common cause of cancer-related death worldwide. Curative treatments are applicable in a minority of selected patients. HCCs most likely arise from chronic liver diseases; thus, liver transplantation theoretically offers the best chances of a cure. However, the broad use of transplantation for HCC faces various constraints, advocating for surgical resection as one of the preferred options provided there is adequate patient selection and anticipation of the postoperative risk of liver failure.
Various non-invasive tools have been promising in assessing liver functional reserve and portal pressure; they are increasingly seen as valuable for refining patients' evaluation and future liver volume optimization strategies. Furthermore, direct-acting anti-hepatitis C agents together with the growing prevalence of metabolic-associated fatty liver diseases convey new considerations. Laparoscopic and robotic approaches currently compete with ablation techniques and open procedures. Their minimally invasive nature as well as the regained attention given to perioperative immunotherapy-based protocols are new assets likely to amend both indications and results of the surgical treatment of HCC.
With this Special Issue in Cancers, we welcome original pre-clinical or clinical research articles and comprehensive or systematic reviews focusing on the surgical treatment of HCC through the spectrum of evolving tools, strategies, indications, and techniques.
Dr. Christian Hobeika
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hepatocellular carcinoma
- hepatectomy
- liver function
- future liver volume optimization
- liver failure
- cirrhosis
- MAFLD
- portal hypertension
- minimally invasive surgery
- immunotherapy
